QualityCounts.com  
Home iHerb Int Antiaging Sys LEF at Amazon LEF at LEF Amazon.com Contact
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:
 iHerb
 Int. Anti-aging Systems
 Puritan's Pride
 Vitamin Shoppe
 The Karaoke Channel
 Vital Choice Seafood
 
Please support this website by purchasing via the links on the website.

Home > Anti-aging Research > DHEA

Dehydroepiandrosterone-sulphate (DHEA)

Specific Recommendations:

Related Topics:

7-Keto DHEA:

  • Pure Encapsulations - 7-Keto DHEA (100mg) - 60ct
  • 7-Keto DHEA The Fat-Burning Metabolite of DHEA - Life Extension Magazine, 5/05 - "By offering many of the advantages of DHEA supplementation without conversion to estrogen and testosterone, 7-Keto affords older adults the opportunity to further promote their health and longevity even when their levels of the so-called “downstream” hormones are already optimal. Moreover, considering 7-Keto’s demonstrated ability to improve body composition, it is highly likely that this DHEA metabolite will become a staple supplement for many aging adults"
  • The Death of Anti-Aging Supplements? - Life Extension Magazine, 3/03 - "During these many trials, researchers routinely found that when taken daily, DHEA supplements effectively reduced depressive episodes and enhanced mood. In fact, according to one major study in the UK, as many as 67% of men and 82% of women reported a noticeable decrease in their depressive symptoms while taking as little as 25 mg/day of DHEA ... DHEA is recognized as one of the major adrenal androgens, and many of its abilities have been well-documented. We have learned through years of research that it enhances the immune system, fights osteoporosis, lowers hyperglycemia (high blood sugar) and may even help to mount a defense against HIV"
  • Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens - J Clin Endocrinol Metab 1999 Jun;84(6):2170-6 - "Serum testosterone and dihydrotestosterone remained unchanged after DHEA administration. In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs. 700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)]" - That's a 40% increase in the bad estrogen!!!  On top of that, if you are taking testosterone, that increases estrogen also.  See aromatization.

Other News:

Abstracts:

  • Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial - Eur J Obstet Gynecol Reprod Biol. 2016 May;200:11-5 - "The study group received DHEA 25mg three times daily for 12 weeks before the IVF/ICSI cycles and the control group did not receive DHEA ... Controlled ovarian stimulation (COH) ... The DHEA group had significantly higher clinical pregnancy rate (32.8% vs 15.7%, p=0.029), ongoing pregnancy rate (28.5% vs 12.8%) ... DHEA was well tolerated by the patients and was associated with less COH days and gonadotropins doses" - See Pure Encapsulations 7-keto DHEA.
  • Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer - Prostate. 2015 Nov 30 - "We confirmed that low serum DHEA levels in prostate cancer patients were related to high Gleason score and advanced clinical stage. These results suggest that serum DHEA level may be a useful prognostic factor in prostate cancer patients"
  • Dehydroepiandrosterone-sulfate (DHEAS) promotes MIN6 cells insulin secretion via inhibition of AMP-activated protein kinase - Biochem Biophys Res Commun. 2013 Oct 8 - "Although it has the property of anti-diabetes, the long-term effect of DHEAS on insulin secretion in beta-cells is still unclear. In this study, the effect of DHEAS on the insulin secretion activity in MIN6 cell lines in vitro was assessed. Insulin biosynthesis and secretion were stimulated by DHEAS for 24 h. DHEAS inhibited the AMPK activation and upregulated the expression of ACC-1. These findings indicate that DHEAS may exert prominent stimulatory effects on insulin secretion partly via AMPK inhibition and ACC-1 upregulation"
  • Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo controlled trials - J Clin Endocrinol Metab. 2013 Jul 3 - "An extensive Medline Embase and Cochrane search was performed ... DHEA supplementation in elderly men can induce a small but significant positive effect on body composition which is strictly dependent on DHEA conversion into its bioactive metabolites such as androgens or estrogens"
  • Low Dehydroepiandrosterone Sulfate is Associated With Increased Risk of Ischemic Stroke Among Women - Stroke. 2013 May 23 - "Between 1989 and 1990, 32 826 women without prior stroke in the Nurses' Health Study, an observational cohort, provided blood samples and were followed up for cardiovascular events ... Conditional on matching factors, the lowest DHEAS quartile exhibited a relative risk of 1.30 for ischemic stroke (95% confidence interval, 0.88-1.94), compared with the highest quartile and marginally unchanged when adjusted for confounders (relative risk=1.33; 95% confidence interval, 0.87-2.02). When modeled as a binary variable dichotomized at the lowest quartile, women with low DHEAS (≤the lowest quartile) had a significantly increased multivariable adjusted risk of ischemic stroke compared with those with higher levels (relative risk=1.41; 95% confidence interval, 1.03-1.92)"
  • A Randomized Double-Blinded Placebo-Controlled Trial on the Effect of Dehydroepiandrosterone for 16 Weeks on Ovarian Response Markers in Women with Primary Ovarian Insufficiency - J Clin Endocrinol Metab. 2012 Nov 8 - "Preliminary reports have shown encouraging effects of dehydroepiandrosterone (DHEA) in women with poor ovarian reserve undergoing assisted reproduction and primary ovarian insufficiency (POI), although data from randomized controlled trials are limited ... Eligible subjects were randomized into the DHEA group (n = 10), who received DHEA (LiveWell, 25 mg three times a day), or the placebo group (n = 12), who received placebo for 16 wk according to a computer-generated randomization list ... No significant change in serum AMH and FSH levels had been detected throughout the study. AFC and ovarian volume were significantly higher at wk 12 and 20, respectively, in the DHEA group. Significantly more women having at least one follicle of 10 mm or greater at wk 12, 16, and 20 were found in the DHEA group. Serum testosterone and DHEA sulfate levels along with higher estradiol levels were significantly higher in the DHEA group"
  • The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: A report of gender differences - Eur Neuropsychopharmacol. 2012 Oct 17 - "Data regarding the efficacy of dehydroepiandrosterone (DHEA) in the treatment of hypoactive sexual desire disorder (HSDD) are scarce and inconsistent. We aimed to determine possible gender differences in the efficacy of DHEA as a treatment for HDSS. Postmenopausal women (n=27), and men (n=21) with HSDD, were randomized to receive either DHEA 100mg daily or placebo for 6 weeks in a controlled, double blind study ... In women only, significant interaction effects were observed for sexual arousal (p<0.05), satisfaction (p<0.05), and cognition (trend; p=0.06). For arousal, a significant improvement was observed for the DHEA treated group at 6 weeks (p=0.001). Significant correlations were observed between bioavailable T and sexual cognitions, arousal and orgasm, while DHEAS was correlated with satisfaction. In the men, significant correlations were observed between testosterone and arousal (r=.45), sexual drive (r=.50) and orgasm (r=.55). In women with HSDD, DHEA treatment had a significant beneficial effect on arousal, whereas no efficacy was demonstrated in men, indicating a possible gender difference. This improvement seems to be mediated via DHEA's metabolism to testosterone. Our positive results suggest that the neurosteroid DHEA may be effective as a treatment for women with HSDD if administered at a dose of at least 100mg per day"
  • Diferential Effect of Oral Dehydroepiandrosterone-Sulphate on Metabolic Syndrome Features in Pre- and Postmenopausal Obese Women - Clin Endocrinol (Oxf). 2011 Dec 2 - "To analyze the effect in obese pre- and postmenopausal women of a daily dose of 100 mg Dehydroepiandrosterone-sulphate (DHEA-S) provided over a period of 3 months as replacement therapy against Metabolic-Syndrome ... DHEA-S replacement produced weight loss in the obese women studied. Moreover, waist-circumference, glucose and systolic and diastolic blood pressure, among other Metabolic-Syndrome parameters, improved in the postmenopausal group, who showed a significant reduction in the total Metabolic-Syndrome Score (P<0.05). In contrast, in premenopausal women, the effect of DHEA-S was limited to obesity parameters and no effect was observed on Metabolic-Syndrome components. No significant changes were evident in the placebo group. Conclusions:  An oral dose of DHEA-S is useful for weight loss. In obese postmenopausal women the hormone significantly improves plasma biochemical levels and anthropometric characteristics, leading to a better metabolic profile, which highlights the usefulness of this therapy against Metabolic-Syndrome in this group of women"
  • Dehydroepiandrosterone protects against oxidative stress-induced endothelial dysfunction in ovariectomized rats - J Physiol. 2011 Mar 14 - "The present results suggest an important action of DHEA, improving endothelial function in OVX rats by acting as antioxidant and enhancing the NO bioavailability"
  • Cortisol, dehydroepiandrosterone sulphate, their ratio and hypertension: evidence of associations in male veterans from the Vietnam Experience Study - J Hum Hypertens. 2011 Feb 10 - "Cortisol and the cortisol:DHEAS ratio were positively associated with hypertension (P<0.001), whereas DHEAS was negatively associated; the latter relationship was attenuated to non-significance (P=0.06) in models that adjusted for age, sociodemographics, place of service, health behaviours and BMI. The present analyses provide confirmation of a positive association between cortisol and the cortisol:DHEAS ratio and population hypertension"
  • Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women - J Am Geriatr Soc. 2010 Sep;58(9):1707-14 - "DHEA supplementation resulted in gains in lower extremity strength (from 459 +/- 121 N to 484 +/- 147 N; P=.01). There was also improvement in Short Physical Performance Battery score, a composite score that focuses on lower extremity function, in those taking DHEA (from 10.1 +/- 1.8 to 10.7 +/- 1.9; P=.02). There were significant changes in all hormone levels, including DHEAS, estradiol, estrone, and testosterone, and a decline in sex hormone-binding globulin levels in those taking DHEA ... CONCLUSION: DHEA supplementation improved lower extremity strength and function in older, frail women involved in a gentle exercise program of chair aerobics or yoga. No changes were found in BMD either due to small sample size, short duration of study or no effect. The physical function findings are promising and require further evaluation as frail women are at high risk for falls and fracture"
  • DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women - J Clin Endocrinol Metab. 2010 Aug 25 - "Women in the lowest DHEA-S tertile had higher CVD mortality (17% 6-yr mortality rate vs. 8%; log-rank P = 0.011), and all-cause mortality (21 vs. 10%; P = 0.011) compared with women with higher DHEA-S levels. The increased CVD mortality risk [hazard ratio (HR) = 2.55; 95% confidence interval (CI) = 1.19-5.45] remained unchanged after adjustment for multiple CVD risk factors (HR = 2.43; 95% CI = 1.06-5.56) but became nonsignificant when further adjusting for the presence or severity of angiographic obstructive CAD (HR = 1.99; 95% CI = 0.87-4.59). Results were similar for all-cause mortality. Lower DHEA-S levels were only marginally but not independently associated with obstructive CAD"
  • Protective effects of dehydroepiandrosterone on atherosclerosis in ovariectomized rabbits via alleviating inflammatory injury in endothelial cells - Atherosclerosis. 2010 Aug 3 - "The risk for atherosclerosis is increased in postmenopausal women. Dehydroepiandrosterone (DHEA) is postulated to have anti-atherogenic properties ... DHEA administration alleviates efficiently the early pathologic damage of atherosclerosis, increases the serum NO level, and up-regulates the endothelial cell estrogen receptor (ER) expression of ovariectomized rabbits. DHEA in vitro significantly promotes NO synthesis, suppresses MDA and MCP-1 secretion of endothelial cells, and decreases ICAM-1, VCAM-1 and E-selectin expression in HUVECs; neither selective ERα antagonist (methyl-piperidino-pyrazole, MPP) nor ERβ antagonist (R,R-tetrahydrochrysene, R,RTHC) can abolish these effects. Furthermore, DHEA reduces CCR2, LFA-1 and VLA-4 expression in U937 cells, which in turn inhibits the adherence of monocytes to the injured endothelial cells. DHEA significantly decreased the LPS-induced NF-κB transcription"
  • Role of androgens in women's sexual dysfunction - Menopause. 2010 Jun 8 - "Significantly lower levels of two precursor hormones, dehydroepiandrosterone sulfate and androstene-3beta,17beta-diol, were found in women with sexual dysfunction ... Although the significance of the former awaits further study, androgen deficiency in women with HSDD was not confirmed. Given the unknown long-term effects of testosterone supplementation, women receiving testosterone therapy should be informed that a deficit of testosterone activity in women with HSDD has not been identified"
  • Elevated serum dehydroepiandrosterone sulphate level correlates with increased risk for metabolic syndrome in the elderly men - Eur J Clin Invest. 2009 Dec 30 - "The highest DHEA-S quartile group had increased risk for metabolic syndrome (odds ratio = 2.68, 95% confidence interval: 1.44-5.01, P < 0.01) compared with the lowest quartile group. The mean serum DHEA-S level increased with increasing number of metabolic syndrome components. Conclusions The prevalence of metabolic syndrome increases with elevated DHEA-S levels among elderly Taiwanese men. Thus, elevated serum DHEA-S level should be treated as an important risk factor for metabolic syndrome in elderly men"
  • Circulating Dehydroepiandrosterone Sulfate Concentrations during the Menopausal Transition - J Clin Endocrinol Metab. 2009 May 26 - "Cross-sectional analysis at baseline, showed a linear decline in circulating log-transformed DHEAS with increasing age for either the entire cohort (2.81% per year) for individual ethnicities. A similar negative association with baseline age (2.44% decline per year) was seen in longitudinal linear mixed modeling including observations from premenopause through late postmenopause, an additional 0.33% decline/year"
  • Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration - Menopause. 2009 May 8 - "The present data show that local daily intravaginal DHEA administration at DHEA doses of 3.25-13 mg was able to rapidly and efficiently achieve correction of all the signs and symptoms of vaginal atrophy and improve sexual function and caused no or minimal changes in serum sex steroid levels, which all remain within the normal postmenopausal range, thus avoiding the risks of all estrogen formulations"
  • Intravaginal dehydroepiandrosterone (Prasterone), the physiological and a highly efficient treatment of vaginal atrophy - Menopause. 2009 May 8 - "All three doses (0.25%, 0.5%, and 1.0%) of DHEA ovules applied daily intravaginally induced a highly significant beneficial change in the percentage of vaginal parabasal and superficial cells and pH as well as in the most bothersome symptom at 2 weeks. At the standard 12-week time interval, 0.5% DHEA caused a 45.9 +/- 5.31 (P < 0.0001 vs placebo) decrease in the percentage of parabasal cells, a 6.8 +/- 1.29% (P < 0.0001) increase in superficial cells, a 1.3 +/- 0.13 unit (P < 0.0001) decrease in vaginal pH, and a 1.5 +/- 0.14 score unit (P < 0.0001) decrease in the severity of the most bothersome symptom. Similar changes were seen on vaginal secretions, color, epithelial surface thickness, and epithelial integrity. Comparable effects were observed at the 0.25% and 1.0% DHEA doses ... Local Prasterone, through local androgen and estrogen formation, causes a rapid and efficient reversal of all the symptoms and signs of vaginal atrophy with no or minimal changes in serum steroids, which remain well within the normal postmenopausal range. This approach avoids the fear of systemic effects common to all presently available estrogen formulations and adds a novel physiological androgenic component to therapy"
  • Low serum levels of sex-steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations - J Clin Endocrinol Metab. 2009 Mar 24 - "Dry mouth symptoms decreased during DHEA therapy ... Disease manifestations in primary Sjogren's syndrome were associated with low sex hormone levels, dry mouth symptoms with low androgens and dry eyes with low estrogens. Exogenous DHEA was preferentially transformed into androgens rather than into estrogens"
  • Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term oral dehydroepiandrosterone treatment in postmenopausal women - Menopause. 2008 Dec 17 - "after prolonged treatment of postmenopausal women with 25 mg/d of dehydroepiandrosterone ... Mean baseline androgen levels at day 1 and month 3 in the treated group (seven evaluable women) were the following: dehydroepiandrosterone, 1.82 and 3.56 ng/mL; dehydroepiandrosterone sulfate, 0.96 and 3.37 mug/mL; 5-androstene-3beta,17beta-diol, 0.32 and 0.66 ng/mL; androstenedione, 0.50 and 0.86 ng/mL; testosterone, 17.9 and 28.7 ng/dL; dihydrotestosterone, 6.91 and 17.4 ng/dL; and 3alpha-androstanediol glucuronide, 2.66 and 10.7 ng/mL, respectively; these increases were significant. Small changes (-6% to 16%) were observed from month 3 to month 6. Nonsignificant increases were observed in baseline estrone and estradiol levels and in Cmax and AUC0-24h values for the androgens and estrogens from day 1 to months 3 and 6 of treatment. Sex hormone-binding globulin levels were unchanged, but free testosterone increased significantly from day 1 to month 3 ... Changes in baseline values over time differed significantly between the groups for all hormones except estrone and estra"
  • Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients - J Psychiatr Res. 2008 Aug 13 - "Mirtazapine significantly reduced both COR and DHEA-S concentrations, but had no impact on the COR/DHEA-S ratio"
  • Serum DHEA-S Level Is Associated with the Presence of Atherosclerosis in Postmenopausal Women with Type 2 Diabetes Mellitus - Endocr J. 2008 May 21 - "intima-media thickness (IMT) ... Although simple regression analysis showed that log(DHEA-S) and IGF-I in men and log(DHEA-S) in women were significantly and inversely correlated with baPWV and IMT, only log(DHEA-S) in women was still significantly and inversely correlated with these atherosclerotic parameters after multiple regression analysis was adjusted for age, duration of diabetes, BMI, HbA(1C), systolic blood pressure, LDL-Cholesterol (C), serum creatinine, and smoking (Brinkman index). Serum DHEA-S level seemed to be associated with atherosclerosis in diabetic postmenopausal women independent of age, body stature, diabetic status, and other atherosclerotic risk factors, and might be a useful addition to other parameters for assessing the risk of atherosclerosis in this population" - See DHEA at Amazon.com.
  • Serum Dehydroepiandrosterone Sulfate Levels Predict Longevity in Men: 27-Year Follow-Up Study in a Community-Based Cohort (Tanushimaru Study) - J Am Geriatr Soc. 2008 Apr 18 - "in men after adjustments for age, systolic blood pressure, and fasting plasma glucose showed significantly (log-rank stat =10.6; P<.001) greater longevity in the highest group (200 mug/dL) than in the moderate (130-199 mug/dL) or lowest groups (129 mug/dL)"
  • Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial - Osteoporos Int. 2007 Dec 15 - "Among older healthy adults, daily administration of 50 mg of DHEA has a modest and selective beneficial effect on BMD and bone resorption in women, but provides no bone benefit for men"
  • DHEA sulfate levels are associated with more favorable cognitive function in women - J Clin Endocrinol Metab. 2007 Dec 11 - "In the multiple linear regression analysis the DHEAS term made a significant independent positive contribution to the Controlled Oral Word Association Test score, a measure of executive function. In addition, women with a DHEAS level in the highest tertile who also had more than 12 years of education performed better on both Digit Span Forward and Digit Span Backward tests which are tests of simple concentration and working memory respectively"
  • Dehydroepiandrosterone and monoamines in the limbic system of a genetic animal model of childhood depression - Eur Neuropsychopharmacol. 2007 Aug 20 - "The results from the current study may imply that treatment with DHEA could be a promising novel therapeutic option for depressed children and adolescents that fail to respond to common (monoaminergic) antidepressant treatments"
  • Dehydroepiandrosterone administration counteracts oxidative imbalance and AGE formation in type 2 diabetic patients - Diabetes Care. 2007 Aug 17 - "Data indicate that DHEA treatment ameliorates the oxidative imbalance induced by hyperglycaemia, down-regulates the TNFalpha/TNFalpha receptors system and prevents AGE formation, suggesting a beneficial effect on the onset and/or progression of chronic complications in type 2 diabetic patients"
  • Changes in Serum Sex Hormone Profiles after Short-term Low-dose Administration of Dehydroepiandrosterone (DHEA) to Young and Elderly Persons - Endocr J. 2007 Mar;54(1):153-62 - "In subjects who were older than 41 yrs. (older group) serum androstenedione and estradiol levels were elevated after the DHEA administration. Significant negative correlations were observed between the serum DHEA concentration and the serum concentration of fasting insulin, HOMA-R, leptin, and high-sensitivity C-reactive protein for all subjects. Daily administration of 25 mg DHEA increased the serum DHEA, DHEAS, androstenedione, and estradiol levels of the subjects of the older group to the same level as that of younger subjects"
  • DHEA in elderly women and DHEA or testosterone in elderly men - N Engl J Med. 2006 Oct 19;355(16):1647-59
  • Effects of DHEA Replacement Therapy on Bone Mineral Density in Older Adults: A Randomized, Controlled Trial - J Clin Endocrinol Metab. 2006 May 30 - "DHEA replacement therapy for 1 yr improved hip BMD in older adults and spine BMD in older women"
  • Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2 - Endocr J. 2005 Dec;52(6):727-33 - "DHEA may act at multiple steps in the regulation of glucose metabolism in the liver"
  • Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function - Urology. 2005 Sep;66(3):597-601 - "Although DHEA-S levels were significantly lower and E2 levels were greater in the men with aging male symptoms according to the AMS, the DHEA-S and FT levels were significantly lower in the men with sexual dysfunction, as determined by the IIEF score. Serum DHEA-S and FT levels and age correlated significantly with the IIEF scores"
  • Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes - Atherosclerosis. 2005 Aug;181(2):339-44 - "evaluated intima-media thickness (IMT) and plaque score (PS) ... Negative correlations were found between DHEA-S concentration and IMT (r=-0.298, P<0.0001) and between DHEA-S concentration and PS (r=-0.308, P<0.0001). IMT and PS were significantly greater in patients with lower concentrations of DHEA-S (<1000ng/ml) than in patients with higher concentrations of DHEA-S"
  • Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women - Diabetes. 2005 Mar;54(3):765-9 - "replacement therapy with 50 mg of DHEA for 12 weeks significantly increased insulin sensitivity in hypoadrenal women, thereby suggesting that DHEA replacement could have a potential impact in preventing type 2 diabetes"
  • Dehydroepiandrosterone Monotherapy in Midlife-Onset Major and Minor Depression - Arch Gen Psychiatry, 2/05 - "Six weeks of DHEA administration was associated with a significant improvement in the 17-Item Hamilton Depression Rating Scale and the Center for Epidemiologic Studies Depression Scale ratings"
  • Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and Men: A Randomized Controlled Trial - JAMA. 2004 Nov 10;292(18):2243-8 - "DHEA replacement could play a role in prevention and treatment of the metabolic syndrome associated with abdominal obesity"
  • Dehydroepiandrosterone Relations to Dietary and Lifestyle Variables in a General Population Sample - Annals of Nutrition & Metabolism 2003;47:158-164 - "DHEA declines sharply with age and there is some evidence that the decline may be sharper in men than in women. Protein intake was significantly inversely associated with plasma levels of DHEA, whereas other dietary factors, energy expenditure and anthropometric variables were unrelated to this hormone"
  • Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia - Archives of General Psychiatry, 2/03 - "Results indicated significant improvement in negative symptoms (P<.001), as well as in depressive (P<.05) and anxiety (P<.001) symptoms in individuals receiving DHEA. This effect was especially noted in women"
  • Double-blind treatment of major depression with dehydroepiandrosterone - Am J Psychiatry 1999 Apr;156(4):646-9 - "DHEA was associated with a significantly greater decrease in Hamilton depression scale ratings than was placebo. Five of the 11 patients treated with DHEA, compared with none of the 11 given placebo, showed a 50% decrease or greater in depressive symptoms"
  • Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens - J Clin Endocrinol Metab 1999 Jun;84(6):2170-6 - "Serum testosterone and dihydrotestosterone remained unchanged after DHEA administration. In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs. 700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)]" - That's a 40% increase in the bad estrogen!!!  On top of that, if you are taking testosterone, that increases estrogen also.  See aromatization.
  • Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study - Urology. 1999 Mar;53(3):590-4 - "Our results suggest that oral DHEA treatment may be of benefit in the treatment of ED."
  • Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection - Immunology. 1999 Feb;96(2):291-7
  • DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet - Am J Physiol. 1997 Nov;273(5 Pt 2):R1704-8 - "These results show that DHEA has a protective effect against accumulation of visceral fat and development of muscle insulin resistance in rats fed a high-fat diet."
  • Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women - J Clin Endocrinol Metab. 1997 Oct;82(10):3498-505 - "a finding of particular interest for both the prevention and treatment of osteoporosis."
  • Dehydroepiandrosterone (DHEA) treatment of depression - Biol Psychiatry. 1997 Feb 1;41(3):311-8 - "These preliminary data suggest DHEA may have antidepressant and promemory effects"
  QualityCounts.com Anti-aging Newsletter
Newsletter Sign-up
Add to Netvibes

Netvibes basic (free)

Join QualityCounts.com on Facebook